Please cite these articles when referring to BAO:

Abeyruwan, S.; Vempati, U.; Küçük, H.; Visser, U, Koleti, A.; Mir, A.; Sakurai, K.; Chung, C.; Bittker, J.; Clemons, P.; Brudz, S.; Siripala, A.; Morales, A.; Romacker, M.; Twomey, D.; Bureeva, S.; Lemmon, V., Schürer, S. “Evolving BioAssay Ontology (BAO): Modularization, Integration and Applications” J Biomed Semantics, 2014, doi:10.1186/2041-1480-5-S1-S5.

Vempati, U.D.; Przydzial, M.J.; Chung, C.; Abeyruwan, S.; Mir, A.; Sakurai, K.; Visser, U.; Lemmon, V.P.; Schürer, S.C. “Formalization, Annotation and Analysis of Diverse Drug and Probe Screening Assay Datasets using the BioAssay Ontology (BAO).” PLoS One, 2012, doi:10.1371/journal.pone.0049198.



The lack of established standards to describe and annotate biological assays and screening outcomes in the domain of drug and chemical probe discovery is a severe limitation to utilize public and proprietary drug screening data to their maximum potential. We have created BioAssay Ontology (BAO) to establish common reference metadata terms and definitions required for describing relevant information of low-and high-throughput drug and probe screening assays and results. The main objectives of BAO are to enable effective integration, aggregation, retrieval, and analyses of drug screening data.  BAO is a formal OWL-DL ontology and captures deep knowledge about screening assays and their results enabling classifications that enable data analysis and facilitate meaningful retrieval of screening results.